Please note that following on from a request received from the company, NICE will be undertaking an appraisal of Sugemalimab with chemotherapy for untreated advanced non-small-cell lung cancer. The appraisal is anticipated to begin during late September 2026 when we will write to you about how you can get involved. Information on the appraisal can be found under ID6758.